Dr. Scott K. Dessain

Dr. Scott K. Dessain, MD, PhD, is a distinguished physician-scientist and a leading innovator in antibody therapeutics and translational immunology. He serves as an attending physician in Hematology/Oncology at Lankenau Medical Center and is the Founder and Chief Medical Officer of Immunome, a biotechnology company focused on harnessing the immune system for cancer and infectious disease therapeutics. Dr. Dessain earned his medical degree and PhD in Molecular Biophysics and Biochemistry from Yale University, completed his residency in Internal Medicine at Brigham and Women’s Hospital, and pursued fellowship training in Medical Oncology at the Dana-Farber Cancer Institute. He is board-certified in Internal Medicine and Medical Oncology and is recognized for his leadership in advancing antibody discovery platforms.

A trailblazer in developing next-generation monoclonal antibody technologies, Dr. Dessain has been instrumental in establishing novel methods to isolate therapeutic antibodies directly from human memory B cells. His work has significantly advanced the identification of potent antibodies targeting tumor-specific antigens, contributing to the development of immune-based therapies for solid tumors and infectious diseases. Dr. Dessain holds multiple patents, has authored numerous peer-reviewed publications, and continues to drive innovation at the intersection of academic research and biotechnology entrepreneurship.

Beyond his scientific achievements, Dr. Dessain is a dedicated mentor and advocate for translational research. He has guided physician-scientists in navigating the complexities of academic-industry partnerships and continues to foster innovation through mentorship and collaboration. His contributions have had a lasting impact on the field of antibody therapeutics, shaping strategies for the rapid translation of immune-targeted therapies into clinical development.